The invention relates to targeted RNA interference (RNAi) for the prevention and treatment of cardiomyopathy by inhibiting the expression of the enhancer RNA 22 (eRNA-22). An RNAi agent, a nucleic acid vector encoding a RNAi agent, a virus carrying such vector and a cell capable of producing such virus are provided.